Breast Cancer Clinical Trial
Official title:
Near-Infrared Imaging of Fluorescent Dyes for Lymph Node Mapping
The goal of this clinical research study is to find lymph nodes before surgery using a dye
called indocyanine green (IC-Green).
Objectives:
1. To determine the feasibility of using nonradioactive optical imaging techniques with
indocyanine green (ICG) as a fluorescent contrast agent to identify all axillary lymph
nodes.
2. To determine the feasibility of using nonradioactive optical imaging techniques with
ICG as a fluorescent contrast agent to characterize lymphatic architecture and function
in women with breast cancer who are scheduled for axillary node dissection.
IC-Green Injections:
If you are found to be eligible to take part in this study, a member of the study staff will
give you between 6-16 injections of IC-Green through a needle in your hand, arm, and breast.
The study doctor will discuss the number of injections that you will receive in more detail.
The injections will be given after you are under anesthesia.
These IC-Green injections will allow researchers to see the flow of the liquid through your
body during imaging and locate the lymph nodes that will be removed during your standard of
care surgery. After all of the IC-Green injections have been given, the imaging procedure
will begin. Researchers will use an experimental camera that shines a special red light onto
your skin causing the IC-Green to glow when the images are taken. The red light is like the
red light in a grocery store scanner. The imaging procedure will take about 1 hour to
complete.
Before the IC-Green injections and during imaging, a member of the research staff will
monitor and record your vital signs (blood pressure, breathing rate, heart rate, and
temperature).
After the IC-Green injections, a study staff member will closely monitor the injection site
for possible side effects every 15 minutes during the first hour, and then every 30 minutes
during the second hour. A study staff member will call you the next day and ask you to take
your temperature. This phone call should last about 5 minutes.
Follow-Up Evaluation:
If you spend the night in the hospital after your surgery, a study staff member will visit
you for a follow-up the day after surgery. At this visit, your temperature will be recorded
and you will be asked how you are feeling and if you have had any side effects. The visit
should last about 10 minutes.
If you do not spend the night in the hospital after surgery, you will be contacted by phone
the day after surgery. You will be asked the same questions described above, as well as what
your temperature is. The phone call should last about 10 minutes.
Length of Study:
After all of the images have been taken, and the follow-up evaluation is complete, your
participation in this study will be over.
This is an investigational study. IC-Green is FDA approved and commercially available for
mapping heart, liver, and eye function. The use of IC-Green for mapping the lymph nodes in
breast cancer patients is investigational.
The experimental camera, and the images taken with it, are being used for research purposes
only and will not be used to manage your treatment.
Up to 20 patients will be take part in this study. All will be enrolled at MD Anderson.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |